Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Brii Biosciences's share price for the quarter that ended in Dec. 2023 was HK$2.28. Brii Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 729.39 Mil. Therefore, Brii Biosciences's market cap for the quarter that ended in Dec. 2023 was HK$1,663.00 Mil.
Brii Biosciences's quarterly market cap
declined
from Dec. 2022 (HK$5,359.49 Mil) to Jun. 2023 (HK$2,285.35 Mil) and
declined
from Jun. 2023 (HK$2,285.35 Mil) to Dec. 2023 (HK$1,663.00 Mil).
Brii Biosciences's annual market cap
declined
from Dec. 2021 (HK$23,805.65 Mil) to Dec. 2022 (HK$5,359.49 Mil) and
declined
from Dec. 2022 (HK$5,359.49 Mil) to Dec. 2023 (HK$1,663.00 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Brii Biosciences's Enterprise Value for Today is HK$-1,993.32 Mil.
Brii Biosciences Market Cap Historical Data
The historical data trend for Brii Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Brii Biosciences's Market Cap
For the Biotechnology subindustry, Brii Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's Market Cap falls into.
Brii Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Brii Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences (HKSE:02137) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Brii Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Brii Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Brii Biosciences (HKSE:02137) Business Description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02137 has been successfully added to your 